Kythera brings in $30mm through its Series C round

Jafco has led Kythera Biopharmaceuticals's (dermatology therapeutics) $30mm Series C round. Fellow first-time backers BBT Capital Management, Apothecary Capital, and PFM were joined by returning investors Versant Ventures, Arch Venture Partners, Prospect Venture Partners, Altitude Life Science Ventures, and Wilson Sonsini Goodrich and Rosati. Kythera has the option to a second tranche of $10mm during the early part of 2009. The company will use the Series C funds to finish Phase II trials of ATX101 for minimally invasive localized fat reduction, and to bring the dermal contouring agent ATX104 and pigment modulation compound ATX202 into the clinic.